Compare AA & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AA | KYMR |
|---|---|---|
| Founded | 1888 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aluminum | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.0B | 10.6B |
| IPO Year | 2016 | 2020 |
| Metric | AA | KYMR |
|---|---|---|
| Price | $42.77 | $112.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 26 |
| Target Price | $67.20 | ★ $107.72 |
| AVG Volume (30 Days) | ★ 2.6M | 608.0K |
| Earning Date | 04-16-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.64% | N/A |
| EPS Growth | ★ 1580.77 | N/A |
| EPS | ★ 3.13 | N/A |
| Revenue | ★ $12,831,000,000.00 | $39,211,000.00 |
| Revenue This Year | $16.05 | $10.61 |
| Revenue Next Year | N/A | $8.17 |
| P/E Ratio | $13.64 | ★ N/A |
| Revenue Growth | ★ 7.87 | N/A |
| 52 Week Low | $31.98 | $54.09 |
| 52 Week High | $84.38 | $130.05 |
| Indicator | AA | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 32.59 | 43.20 |
| Support Level | $42.61 | $110.64 |
| Resistance Level | $53.25 | $120.37 |
| Average True Range (ATR) | 1.51 | 5.10 |
| MACD | -0.58 | -0.57 |
| Stochastic Oscillator | 5.31 | 16.64 |
Alcoa is a vertically integrated aluminum company whose operations include bauxite mining, alumina refining, and manufacturing primary aluminum. It is one of the world's largest bauxite miners and alumina refiners by production volume, but sits outside the top-10 aluminum producers, a list dominated by Chinese companies. Profits are closely tied to prevailing commodity prices along the aluminum supply chain.Alcoa was the first mass producer of aluminum, launching the world-changing Hall-Heroult smelting process in the 1880s, making aluminum affordable. It listed as a public company in 1925. In 2016, Alcoa spun off its automotive and aerospace metal parts segment to focus on mining, smelting, and refining. It bought the 40% unowned balance of AWAC in mid-2024.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.